AMENDMENT TO THE CLAIMS

Please amend the claims as shown below, without prejudice or disclaimer. This listing of the claims replaces all prior listings.

1-46. Cancelled

47. (New) A method for testing a body fluid sample for the presence of antibodies against specific, individual Major Histocompatibility Complex (MHC) antigens, the method comprising:

contacting the sample with a solid support comprising discrete sites, each site comprising recombinant MHC molecules representing a specific, individual MHC antigen, and

detecting the binding or absence of binding of antibodies to the recombinant MHC molecules at each site.

48. (New) The method of claim 47 wherein at least two or more sites comprise recombinant MHC Class I molecules.

49. (New) The method of claim 48 wherein at least two or more sites comprise a MHC Class I heavy chain, β-microglobulin, and a peptide.

50. (New) The method of claim 49 wherein the recombinant MHC Class I heavy chain are synthesized in a prokaryotic expression system.

51. (New) The method of claim 49 wherein the recombinant MHC Class I heavy chain is synthesized in un-glycosylated form.

52. (New) The method of claim 48 wherein at least two or more sites comprise human leukocyte antigens (HLA).

53. (New) The method of claim 52 wherein at least two or more sites comprise a HLA Class I heavy chain, β-microglobulin, and a peptide.

54. (New) The method of claim 53 wherein the HLA Class I heavy chain is synthesized in a prokaryotic expression system.

55. (New) The method of claim 53 wherein the HLA Class I heavy chain is synthesized in un-glycosylated form.

56. (New) The method of claim 49 or 53 wherein said peptide is derived from a human immunodeficiency virus (HIV), a hepatitis C virus (HCV), or an influenza virus.

57. (New) The method of claim 49 or 53 wherein the heavy chain is biotinylated.

58. (New) The method of claim 52 wherein the HLA antigens are selected from the group consisting of A*0101, A*0201, A*0301, A*1101, A*2301, A*2401, A*2501, A*2601, A*2902, A*3001, A*3101, A*3201, A*3301, A*3401, A*3601, A*4301, A*6601, A*6801, A*6901, A*7401, A*8001, B*0702, B*0801, B*1302, B*1401, B*1402, B*1501, B*1502, B*1503, B*1509, B*1512, B*1513, B*1516, B*1801, B*2705, B*3501, B*3701, B*3801, B*3901, B*4001, B*4002, B*4101, B*4201, B*4402, B*4501, B*4601, B*4701, B*4801, B*4901, B*5001, B*5101, B*5201, B*5301, B*5401, B*5501, B*5601, B*5701, B*5801, B*5901, B*6701, B*7301, B*7801, B*8101, B*B201, Cw*0102, Cw*0202, Cw*0304, Cw*0303, Cw*0401, Cw*0501, Cw*0602, Cw*0701, Cw*0802, Cw*1202, Cw*1203, Cw*1402, Cw*1502, Cw*1601, Cw*1701, and Cw*1801.

59. (New) The method of claim 47 wherein the sample is blood or a blood-derived sample.

60. (New) The method of claim 59 wherein the sample is purified plasma.

61. (New) The method of claim 47 wherein the solid support is selected from the group consisting of glass, a glass slide, silica, latex, agarose, alginate, teflon, polystyrene, nylon, plastic, tissue culture plastic, a spherical bead, sepharose, a magnetic bead, a non-magnetic bead, a filter, a membrane, a fibre, a capillary, a nitrocellulose strip, a tube, a plate, a plate comprising multiple wells, and an ELISA plate.

62. (New) The method of claim 47 wherein the antibodies are detected and identified using a method selected from the group consisting of an immunosorbent assay using an antibody conjugated to a label or enzyme, detection of colloidal gold, immunoelectron microscopy, flow cytometry, immunofluorescent detection, and ELISA.

63. (New) The method of claim 47 wherein the antibodies are selected from the group consisting of IgG, IgM, and IgA.

66. (New) The method of claim 47 wherein recombinant MHC molecules representing at least one to 100 MHC antigens are bound to discrete sites on the solid support.

67. (New) The method of claim 52 wherein recombinant MHC molecules representing at least one to 100 HLA antigens are bound to discrete sites on the solid support.

68. (New) A kit for detecting in a body fluid sample the presence of one or more anti-Major Histocompatibility Complex (MHC) antibodies against specific, individual MHC antigens, the kit comprising at least the following components:

a) a solid support comprising discrete sites, each site comprising recombinant MHC molecules representing only one individual MHC antigen; and

b) a moiety capable of direct or indirect detection of anti-MHC-antibodies bound to said recombinant MHC molecules;

wherein the binding or absence of binding of antibodies to the recombinant MHC molecules at each site may be detected.

69. (New) The kit of claim 68 wherein the solid support is selected from the group consisting of glass, a glass slide, silica, latex, agarose, alginate, teflon, polystyrene, nylon, plastic, tissue culture plastic, a spherical bead, sepharose, a magnetic bead, a non-magnetic bead, a filter, a membrane, a fibre, a capillary, a nitrocellulose strip, a tube, a plate, a plate comprising multiple wells, and an ELISA plate.

70. (New) The kit of claim 68 wherein the antibodies are detected and identified using a method selected from the group consisting of an immunosorbent assay using an antibody conjugated to a label or enzyme, detection of colloidal gold, immunoelectron microscopy, flow cytometry, immunofluorescent detection, and ELISA.

71. (New) The kit of claim 68, wherein the identity of the discrete recombinant MHC molecules bound at distinct sites is known.

72. (New) The kit of claim 71, wherein the anti-MHC antibodies are identified by binding to the known recombinant MHC molecules at distinct sites.